Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05688592

Usefulness of PET-CT for Invasive Fungal Infection

Conditions: Invasive Fungal Infections

Sex: All
Ages: 18 Years – N/A
Enrollment: 224
Sponsor: Puerta de Hierro University Hospital

Location: Spain

Summary

The goal of this national multicenter prospective cohort study is to learn about the added value of 18F-FDG (18F-2-fluoro-2-deoxy-D-glucose) PET-CT in invasive fungal disease management. The main questions it aims to answer are:Does the use of 18F-FDG PET-CT allow a better characterization of invasive fungal infection (IFI) (performance) compared to the exclusive use of conventional radiological studies in terms of extension/staging and monitoring of response/follow-up ?Does the systematic and protocolized use of 18F-FDG PET-CT in IFI allow a better management of patients with IFI and increase the prognostic value of the initial evaluation? Participants will undergo systematically a 18F-FDG PET-CT as part of the work-up of their invasive fungal disease. Researchers will compare the performance of 18F-FDG PET-CT with standard management without 18F-FDG PET-CT to see if adds value (diagnostic, prognostic, and changes in management).

Eligibility Criteria

Inclusion criteria:18-year-old adult patientswho are admitted with a diagnosis of invasive fungal infectionwho able to undergo a one 18F-FDG PET-CTwho give their informed consent.Exclusion criteria:concomitant active bacterial infection likely to produce uptake in organs and tissuesrecent surgery in the area of the IFI (in the previous 3 months)other medical conditions that interfere with the development of the study ( e.g., inability to tolerate the performance of the test during the required time, pregnancy)terminal situation.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05688592). StuddyBuddy aggregates publicly available trial information.